Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Lonza AG violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

FDA Inspects Lonza AG: Form 483 with 3 Citations (October 28, 2025)

At a glance: FDA inspected Lonza AG in Switzerland and issued a Form 483 listing 3 inspectional observations following an inspection that concluded 2025-10-28. FDA records classify Lonza AG as a drug substance manufacturer. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Lonza AG
FEI / inspection ID	3002930340
Inspection end date	October 28, 2025
Citation count	3

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — The information provided by the firm does not conform to the{b)(4) ~cifically

The information provided by the firm does not conform to the{b)(4) ~cifically , in the H4> the(b)(4) drug substance (DS) shelflife iS (bH4> at :$(b><4> C. However, the shelflife applied to DS Process Performance Qualification (PPQ) batches (Batch(b)(4) and post- PPQ batches (Batch(b)(4) waS(b)(4)

Observation 2 — The(b)(4) (b)(4) integrity test procedure used for thc(b)(4) does not follow the

The(b)(4) (b)(4) integrity test procedure used for thc(b)(4) does not follow the vendor recommendations (documenC ,n versio~ or SOP CHVI-346656 v2.0 ' ~H4> IOperation of(b><4> and Integrity Test of(b><4> ~(4) {,'. For example: a. (b)(4) l versio11:(b><4> indicates to.___ __, <6H4> for test set-up. However the lbH4> or test set-u is in(b><4> per SOP CHVI-346656 v2.0 Figure<bH4) 'he according to the guidance shown in \U)\~, the(b)(4) Manufacturing Executing System (MES) guidance for the operators. b. (bH4> 1versioi j(bH4> "indicates that the (b><4> should be (bH4> ____________(b>_c4 _>___ ___, _________ This step is not inc.Jnde.dj n SOP CHVI-346656 v2.0 or in th1(b)(4) ¥ES guidance for the ope~ators. c. (b)(4) version(b)(4) indicates to observe and disregarofilill 7 that occur in the(bH4> 2(b)C4> (waiting time), and to observe the.._(b-)(4~>____] __ for:ci,>_m .----- (observation time). i. The(b)(4) lME S instructions indicate to start the timer immediately after the (b)(4) is (b)c4> ruicl.conduct the test for~ c4> 1£ohc:;er_vatio.n..time) witbou\ r entioning any . . ..

Observation 3 — Critical material used to manufacture(b)(4) is -not tracked, maintained, or replaced throughout

Critical material used to manufacture(b)(4) is -not tracked, maintained, or replaced throughout their lifetime. SRer.i:6r.::iJ1v._· ______..., a. The(b><4> ~ grity Tester used fo ~(b)(4) r------, including ther,><4> (b)(4) DS Cb><4> Cb/\4 ) (SAP No: CbH4> installed 4 "6 etweeli1£e_,_____,_____-,...,Cb>< > to avojd ,..". o~the product(b)(4) entering and damaging the instrument. The(b)(4) is not tracked or maintained and is replaced only when damaged. During the FDA inspection oftheCb><4> internty_te~t execution on October 24, 2025, a'(bH4> __________..., coming from the(b)(4) through the(bH4> r~hm~ approx1mately(bH4> Impact of the(b><4> in the results of the(b)(4) ,.------ ~n tegritY. test c_arui ot be discarded. .....,. b. The (b)(4) .---- instrument used to sea\(b)(4) ____,drug substance bags does not have a unique tracking number, and is not maintained or calibrated. c. The/h)/4) used for the CbH4>'~------1or for the_(b_><~4>~_. 1 !b> C4> do not have a preventative mamtenance program. The product contact part of the (b)(4) and replacedb c4> ] however, maintenance ofthe_(b>...;.<4""'">--:-:" ~ t th is "failure-based".

Lonza AG’s FDA history

Argus HQ has recorded 1 total FDA action tied to Lonza AG: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Lonza AG violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Lonza AG

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Inspects Lonza AG: Form 483 with 3 Citations (October 28, 2025). Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-lonza-ag-2025-10-28-3002930340

MLA

"FDA Inspects Lonza AG: Form 483 with 3 Citations (October 28, 2025)." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-lonza-ag-2025-10-28-3002930340.

Chicago

Argus HQ Research. "FDA Inspects Lonza AG: Form 483 with 3 Citations (October 28, 2025)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/483/fda-483-lonza-ag-2025-10-28-3002930340.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_lonza_ag_2025_10_28_3002930340_2025,
  title = {FDA Inspects Lonza AG: Form 483 with 3 Citations (October 28, 2025)},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-lonza-ag-2025-10-28-3002930340},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗